PT-141 Dosage Chart: Units, Limits, Men vs Women

The PT-141 Dosage Chart

Most peptide dosage charts describe a routine: inject this much, at this time, this many days per week. A PT-141 Explore PeRxPT-141On-Demand Intimacy EnhancementView peptide chart cannot work that way, because PT-141 is not a routine. It is an as-needed dose taken before an anticipated event, and the schedule column that anchors every other chart in our catalog simply does not exist here. What replaces it is a pair of hard ceilings, one per 24 hours and 8 per month, which this page covers in their own section. First, the conversion table.

The arithmetic, once. A U-100 insulin syringe holds 100 units per mL, so each unit is 0.01 mL. At the PeRx concentration of 2 mg per mL, one unit holds 20 mcg, which makes the conversion unusually clean: units equals milligrams times 50. The chart below works out the values you will see quoted, with doses per vial counted in full doses.

This page stays on the numbers. For what PT-141 actually is, a melanocortin receptor agonist that works on desire through the brain rather than on blood flow, start with the PT-141 pillar guide Read nextPT-141 Peptide: Benefits, Dosage & Complete GuideThe PT-141 peptide (bremelanotide) is the only FDA-approved medication that targets sexual desire in the brain rather than blood flow in the body. The 2026 guide to how it works, the 1.75-2mg dosage protocol, what to expect from the nausea, and how it compares to Viagra, plus the tanning-drug origin story that's one of the best in pharma.Read article . For the practical run-through of an evening with it, the 45-minute lead time, what onset feels like, and how long the window lasts, that all lives in how to use PT-141 Read nextHow to Use PT-141: Timing and InjectionPT-141 is an on-demand peptide, so the practical questions are about timing more than anything else. Here is when to inject before activity, the step-by-step subcutaneous technique, how long the effects last, and how often you can dose.Read article and is not repeated here.

The Vyleesi Reference Dose

PT-141 is one of the few compounded peptides with an FDA-approved sibling to anchor its numbers. Bremelanotide was approved in June 2019 under the brand name Vyleesi, a prefilled autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label is specific: inject 1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. Do not take more than one dose in 24 hours, and more than 8 doses per month is not recommended.

VYLEESI (bremelanotide injection) Prescribing Information. AMAG Pharmaceuticals. FDA approval June 2019. View study

Two honest caveats come with borrowing that anchor. First, compounded PT-141 is not Vyleesi. The FDA-approved product is a 1.75 mg autoinjector; the compounded version is a multi-dose vial you draw from with an insulin syringe, prepared by a 503A pharmacy under a prescription, and it has not itself been through FDA approval. The active molecule is the same, the delivery and the regulatory status are not. Second, the label leaves real questions open. It states plainly that the duration of efficacy after each dose is unknown and the optimal administration window has not been fully characterized, which is why the 45-minute figure is a floor, not a precise onset time.

Dhillon S, Keam SJ. "Bremelanotide: First Approval." Drugs. 2019;79(14). View study

One more label detail worth knowing because it calibrates expectations: the approval rested on two 24-week randomized trials in 1,247 premenopausal women, and most participants used the drug two to three times per month and no more than once a week. The labeled regimen was never a daily protocol, even in the trials that created it. If a chart you find elsewhere presents PT-141 as a daily peptide, it is describing something the evidence base does not.

PT-141 Units on an Insulin Syringe

The 1.75 mg dose is 0.875 mL at our concentration, which makes syringe choice matter more than it does for most peptides. A 0.3 mL or 0.5 mL insulin syringe physically cannot hold it. You need a standard 1 mL U-100 syringe, and the draw fills it most of the way, to 87.5 units. Standard 1 mL syringes are marked in whole units, so draw to 87 or 88; the 10 mcg difference between those marks is well under one percent of the dose and clinically meaningless.

Drawing 0.875 mL takes a few seconds longer than the tiny draws used for nightly peptides, and injecting it does too. Push slowly. Site choice follows the label: abdomen or thigh, rotated between uses. Technique, angle, and what a normal site reaction looks like are covered step by step in where to inject PT-141 Read nextWhere to Inject PT-141: Sites & TechniquePT-141 is a subcutaneous injection you give about 45 minutes before activity. Because it works centrally in the brain rather than at the injection site, the site you choose is about comfort and rotation, not effect. Here is the practical site map, the step-by-step technique, and how to rotate.Read article , so this page will not duplicate it.

PT-141 Dosage for Men vs Women

This is the most-asked question about PT-141 dosing and it deserves a straight answer rather than two invented numbers. The molecule is identical in men and women; melanocortin receptors do not check your sex before responding. What differs is the evidence. Every number on the FDA label, the 1.75 mg dose, the 45-minute lead time, the 40 percent nausea rate, comes from trials in premenopausal women with HSDD. The label says explicitly that Vyleesi is not indicated for men, or for postmenopausal women, and is not indicated to enhance sexual performance.

That does not mean men were never studied. Bremelanotide began its development life as a candidate for erectile dysfunction and was trialed in men before the program refocused on female HSDD, a history the approval reviews document. What men do not have is a completed approval pathway producing a labeled subcutaneous dose of their own. In practice, prescribers who use PT-141 off-label in men generally work from the same 1.75 mg per-event reference point, because it is the only dose with a full safety package behind it. At PeRx the prescribed dose is 1.75 mg regardless of sex.

Mayer D, Lynch SE. "Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder." Annals of Pharmacotherapy. 2020;54(7). View study

For women, the fuller story, what HSDD actually is, how the approval trials measured desire, and how PT-141 compares with the other approved option, is the subject of PT-141 for women Read nextPT-141 for Women: Low Libido and VyleesiPT-141 is the only FDA-approved medication that targets sexual desire in a woman’s brain rather than blood flow in the body. Here is who it is for, what the approval actually covers, how it compares to the daily pill Addyi, and the honest answers to the questions women ask most.Read article . For men weighing it against the PDE5 inhibitors they already know, PT-141 vs Viagra Read nextPT-141 vs Viagra: How They Work DifferentlyViagra increases blood flow. PT-141 increases desire. They target completely different parts of the sexual response, work through unrelated biological mechanisms, and solve different problems. One is not a replacement for the other. Here is how to know which one you actually need.Read article walks through why a desire drug and an erection drug are answering different questions. Neither group gets a different chart. Same molecule, same concentration, same 87.5 units.

Body weight does not change the number either. The trials used a single fixed dose across participants, not mg-per-kg dosing, and no published data supports scaling the dose to size. A larger person does not need a larger draw.

The PT-141 24-Hour and Monthly Limits

Because PT-141 has no daily schedule, the limits do the work a schedule normally does, and both come straight from the label with documented reasons behind them.

The 24-hour limit exists because of blood pressure. Each dose produces a transient rise, a maximal increase of about 6 mmHg systolic and 3 mmHg diastolic peaking two to four hours after injection, with a small drop in heart rate, and both usually return to baseline within 12 hours. Doses spaced too closely risk additive effects, so the label caps it at one per 24 hours. The same physiology is why Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease, and why the PeRx intake questionnaire asks about both.

The monthly limit exists mostly because of pigmentation. Bremelanotide is a melanocortin agonist, chemically descended from a tanning-peptide research program, and frequent dosing can darken patches of skin, including the face, gums, and breasts. At up to 8 doses per month this focal hyperpigmentation showed up in about 1 percent of trial patients. Dosed daily for 8 days it appeared in 38 percent, and it did not resolve in everyone who stopped. People with darker skin were more likely to develop it. That steep dose-frequency curve is the whole argument for the cap: stay at or under 8 per month and the risk is small, dose like it is a daily peptide and it is not.

One label rule that translates directly to compounded use: Vyleesi carries a stop rule, discontinue after 8 weeks if symptoms have not improved. That is a useful discipline for any as-needed peptide. If several properly timed doses have done nothing for you, the answer is a conversation with your provider, not a bigger draw.

The PT-141 Dosage Calculator Question

A meaningful share of the people searching for PT-141 dosing are looking for a calculator, and the honest answer is that at a fixed concentration you do not need one. Calculators exist for products where the concentration is a variable, powders whose final strength depends on how much diluent was added, so every user faces a different arithmetic problem. A PeRx vial ships fully reconstituted and ready to use at 2 mg/mL, every time. That reduces the entire calculator to one multiplication: units equals milligrams times 50. The prescribed 1.75 mg is 87.5 units. Done.

The only other math worth doing is supply math, and per-event dosing changes how that works too. A 10 mg vial is five full 1.75 mg doses, so at the trial-typical two to three uses per month one vial covers one to two months, and even at the 8-dose monthly ceiling you would use fewer than two vials. Nasal spray products complicate this arithmetic with their own per-spray strengths and absorption questions; that format, which PeRx does not sell, is covered separately in PT-141 nasal spray Read nextPT-141 Nasal Spray vs Injection: The Honest StoryPT-141 nasal spray is a real product category. Compounding pharmacies and online vendors sell it, and PeRx does not. The intranasal version of bremelanotide was shelved during drug development after inconsistent absorption and blood pressure concerns, and the FDA-approved form became a subcutaneous injection instead. This guide covers that history, the honest absorption comparison, and what PeRx offers, as of September 2026.Read article .

PT-141

Every conversion on this page comes from one fact: PeRx PT-141 is compounded at a US-based 503A pharmacy at a fixed 2 mg/mL and prescribed by a licensed provider after a health questionnaire. The vial ships cold overnight with insulin syringes and swabs included, ready to use with no reconstitution needed.

One vial is $229 and holds five full doses at the prescribed 1.75 mg. Nothing is charged until a provider approves the prescription.

One fixed concentration, one line of arithmetic.

Shop Now

Common Questions